AMT-676 is under clinical development by Multitude therapeutics and currently in Phase I for Neuroendocrine Tumors.

Tevimbra is under clinical development by BeiGene and currently in Phase II for Neuroendocrine Tumors. According to GlobalData, Phase II drugs for Neuroendocrine Tumors have a 28% phase transition ...

Exelixis said it was notified by the Food and Drug Administration that its treatment for advanced pancreatic neuroendocrine tumors and advanced extra-pancreatic will not be discussed at a meeting.

Exelixis (EXEL) stock in focus as U.S. FDA leaves out an AdCom in its review of the firm's label expansion for cancer therapy ...

Aman Chauhan, MD, highlights an ongoing phase 2 trial exploring the combination of triapine, a radiation sensitizer, with ...

Award follows extensive pre-clinical, single agent activity data generated by Prof. Colleen Nelson's lab at QUT in 'Aggressive Variant' prostate ca ...

This new funding positions NRMA Insurance as the first corporate partner to support a McGrath Cancer Care Nurse since the ...

Abdera Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and develop tunable precision radiopharmaceuticals for ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, ...